Interpretation of advances in the treatment of esophageal cancer and gastroesophageal junction cancer at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI)
- VernacularTitle:2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO-GI）食管癌及胃食管结合部癌治疗进展解读
- Author:
Jiahe LI
1
,
2
;
Jiayu LU
3
,
4
;
Xuxu ZHANG
1
,
2
;
Xinyao XU
5
,
6
;
Jipeng ZHANG
5
,
6
;
Wei LI
5
,
6
;
Guizhen LI
5
,
6
;
Qiang LU
5
,
6
Author Information
1. 1. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'
2. an, 710038, P. R. China 2. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China
3. Basic Medical College, Air Force Medical University, Xi'
4. an, 710032, P. R. China
5. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'
6. an, 710038, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
gastroesophageal junction cancer;
advanced-stage treatment;
perioperative treatment;
interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(06):771-778
- CountryChina
- Language:Chinese
-
Abstract:
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) was held from January 23 to 25, 2025. Several significant studies on the treatment of esophageal and gastroesophageal junction (GEJ) cancer were presented at the symposium, highlighting notable advances, particularly in the perioperative and advanced settings. Immunotherapy has demonstrated significant promise in the neoadjuvant treatment of esophageal cancer, showing potential to become a standard treatment. Furthermore, the long-term survival benefits of combining immunotherapy with chemotherapy for advanced GEJ cancer were further validated. This article summarizes and interprets the researches presented at the symposium concerning perioperative and advanced treatments for esophageal and GEJ cancers.
